Scholar Rock Holding Corporation (SRRK) Insider Trading

Last 12 months

Insiders sold $19.4M and bought nothing on the open market.

45% of the selling was scheduled in advance under 10b5-1 plans. Chief Executive Officer David Hallal sold $2.45M on Jan 13 outside a plan. The last open-market buy by an executive or director was in Oct 2025.

Net open-market

−$19.4M

0 buys · 26 sales

Under a 10b5-1 plan

45%

of the value sold

Insiders who bought / sold

0 / 13

executives and directors

Last open-market buy

Oct 2025

Oct 7, 2025

Get an email when SRRK's executives or directors buy, or make a large sale outside a plan.

Trades · last 2 years

Date	Insider	Trade	Shares	Price	Value	Of their stake	Filing
Jul 1	Jeffrey S. Flier Director	Sold10b5-1 plan 3 parts	3,053	$53.88 average	$164k	9.9%	Form 4
Jul 1	Michael Gilman Director	Sold10b5-1 plan 3 parts	2,544	$53.87 average	$137k	4.1%	Form 4
Jul 1	Kristina Burow Director	Sold10b5-1 plan 2 parts	3,053	$53.74 average	$164k	0.1%	Form 4
Jul 1	Joshua Reed Director	Sold10b5-1 plan 2 parts	3,053	$53.74 average	$164k	14%	Form 4
Jul 1	Katie Peng Director	Sold10b5-1 plan 3 parts	5,446	$53.87 average	$293k	14%	Form 4
Apr 16	Keith Woods Chief Operating Officer	SoldNo plan	10,220	$49.57	$507k	1.6%	Form 4
Apr 16	Akshay Vaishnaw President of R&D	SoldNo plan	12,246	$49.57	$607k	1.9%	Form 4
Apr 16	Vikas Sinha Chief Financial Officer	SoldNo plan	10,410	$49.57	$516k	1.7%	Form 4
Apr 16	David Hallal Chief Executive Officer	SoldNo plan	30,615	$49.57	$1.52M	1.6%	Form 4
Feb 23	Mo Qatanani CHIEF SCIENTIFIC OFFICER	Sold10b5-1 plan 3 parts	8,484	$47.07 average	$399k	7.9%	Form 4
Feb 17	Mo Qatanani CHIEF SCIENTIFIC OFFICER	SoldNo plan	7,989	$46.53	$372k	7.0%	Form 4
Feb 17	Caryn Parlavecchio CHRO	SoldNo plan	9,035	$46.53	$420k	5.1%	Form 4
Feb 17	Junlin Ho GENERAL COUNSEL	SoldNo plan	9,580	$46.53	$446k	3.8%	Form 4
Feb 17	Jing L. Marantz CHIEF MEDICAL OFFICER	SoldNo plan	4,157	$46.53	$193k	3.2%	Form 4
Jan 22	Mo Qatanani CHIEF SCIENTIFIC OFFICER	Sold10b5-1 plan 2 parts	14,898	$46.71 average	$696k	15%	Form 4
Jan 16	Mo Qatanani CHIEF SCIENTIFIC OFFICER	SoldNo plan	8,406	$44.48	$374k	7.7%	Form 4
Jan 16	Caryn Parlavecchio CHRO	SoldNo plan	6,600	$44.48	$294k	4.2%	Form 4
Jan 16	Junlin Ho GENERAL COUNSEL	SoldNo plan	8,016	$44.48	$357k	3.6%	Form 4
Jan 16	Jing L. Marantz CHIEF MEDICAL OFFICER	SoldNo plan	5,798	$44.48	$258k	5.7%	Form 4
Jan 14	Mo Qatanani CHIEF SCIENTIFIC OFFICER	Sold10b5-1 plan	13,112	$45.20	$593k	11%	Form 4
Jan 13	Vikas Sinha Chief Financial Officer	SoldNo plan	16,755	$42.70	$715k	2.8%	Form 4
Jan 13	Keith Woods Chief Operating Officer	SoldNo plan	16,746	$42.70	$715k	2.8%	Form 4
Jan 13	Akshay Vaishnaw President of R&D	SoldNo plan	20,438	$42.70	$873k	3.3%	Form 4
Jan 13	David Hallal Chief Executive Officer	SoldNo plan	57,450	$42.70	$2.45M	3.2%	Form 4
Dec 16, 2025	Katie Peng Director	Sold10b5-1 plan 2 parts	1,006	$44.09 average	$44k	3.0%	Form 4
Dec 4, 2025	Mo Qatanani CHIEF SCIENTIFIC OFFICER	Sold10b5-1 plan	136,462	$45.21	$6.17M	56%	Form 4
Oct 7, 2025	Srinivas Akkaraju Director	Bought 3 parts	29,599	$39.92 average	$1.18M	0.4%	Form 4
Oct 3, 2025 – Oct 6, 2025	Srinivas Akkaraju Director	Bought 6 parts	500,439	$37.58 average	$18.8M	9.4%	Form 4
Sep 22, 2025	Mo Qatanani CHIEF SCIENTIFIC OFFICER	Sold10b5-1 plan	3,353	$30.67	$103k	3.0%	Form 4
Sep 16, 2025	Katie Peng Director	Sold10b5-1 plan 2 parts	1,006	$32.53 average	$33k	2.9%	Form 4
Sep 16, 2025	Mo Qatanani CHIEF SCIENTIFIC OFFICER	SoldNo plan	3,178	$33.52	$107k	2.8%	Form 4
Aug 18, 2025	Caryn Parlavecchio CHRO	SoldNo plan	2,178	$31.17	$68k	1.4%	Form 4
Jul 16, 2025	Jeffrey S. Flier Director	Sold10b5-1 plan	11,136	$40.02	$446k	32%	Form 4
Jul 8, 2025	Mo Qatanani CHIEF SCIENTIFIC OFFICER	Sold10b5-1 plan	24,066	$34.44	$829k	17%	Form 4
Jun 23, 2025	Jeffrey S. Flier Director	Sold10b5-1 plan 3 parts	31,452	$32.58 average	$1.02M	47%	Form 4
Jun 16, 2025	Katie Peng Director	Sold10b5-1 plan 2 parts	3,031	$31.97 average	$97k	8.0%	Form 4
Jun 16, 2025	Mo Qatanani CHIEF SCIENTIFIC OFFICER	SoldNo plan	3,668	$32.00	$117k	2.6%	Form 4
Jun 16, 2025	Caryn Parlavecchio CHRO	SoldNo plan	6,186	$32.00	$198k	3.8%	Form 4
Jun 16, 2025	Junlin Ho GENERAL COUNSEL	SoldNo plan	7,442	$32.00	$238k	3.2%	Form 4
May 29, 2025	Jeffrey S. Flier Director	Sold10b5-1 plan 2 parts	6,075	$29.73 average	$181k	12%	Form 4

Jul 110b5-1 plan
Jeffrey S. Flier
Director · sold 3,053 at avg $53.88
$164k
9.9% of stake
Jul 110b5-1 plan
Michael Gilman
Director · sold 2,544 at avg $53.87
$137k
4.1% of stake
Jul 110b5-1 plan
Kristina Burow
Director · sold 3,053 at avg $53.74
$164k
0.1% of stake
Jul 110b5-1 plan
Joshua Reed
Director · sold 3,053 at avg $53.74
$164k
14% of stake
Jul 110b5-1 plan
Katie Peng
Director · sold 5,446 at avg $53.87
$293k
14% of stake
Apr 16No plan
Keith Woods
Chief Operating Officer · sold 10,220 at $49.57
$507k
1.6% of stake
Apr 16No plan
Akshay Vaishnaw
President of R&D · sold 12,246 at $49.57
$607k
1.9% of stake
Apr 16No plan
Vikas Sinha
Chief Financial Officer · sold 10,410 at $49.57
$516k
1.7% of stake
Apr 16No plan
David Hallal
Chief Executive Officer · sold 30,615 at $49.57
$1.52M
1.6% of stake
Feb 2310b5-1 plan
Mo Qatanani
CHIEF SCIENTIFIC OFFICER · sold 8,484 at avg $47.07
$399k
7.9% of stake
Feb 17No plan
Mo Qatanani
CHIEF SCIENTIFIC OFFICER · sold 7,989 at $46.53
$372k
7.0% of stake
Feb 17No plan
Caryn Parlavecchio
CHRO · sold 9,035 at $46.53
$420k
5.1% of stake
Feb 17No plan
Junlin Ho
GENERAL COUNSEL · sold 9,580 at $46.53
$446k
3.8% of stake
Feb 17No plan
Jing L. Marantz
CHIEF MEDICAL OFFICER · sold 4,157 at $46.53
$193k
3.2% of stake
Jan 2210b5-1 plan
Mo Qatanani
CHIEF SCIENTIFIC OFFICER · sold 14,898 at avg $46.71
$696k
15% of stake
Jan 16No plan
Mo Qatanani
CHIEF SCIENTIFIC OFFICER · sold 8,406 at $44.48
$374k
7.7% of stake
Jan 16No plan
Caryn Parlavecchio
CHRO · sold 6,600 at $44.48
$294k
4.2% of stake
Jan 16No plan
Junlin Ho
GENERAL COUNSEL · sold 8,016 at $44.48
$357k
3.6% of stake
Jan 16No plan
Jing L. Marantz
CHIEF MEDICAL OFFICER · sold 5,798 at $44.48
$258k
5.7% of stake
Jan 1410b5-1 plan
Mo Qatanani
CHIEF SCIENTIFIC OFFICER · sold 13,112 at $45.20
$593k
11% of stake
Jan 13No plan
Vikas Sinha
Chief Financial Officer · sold 16,755 at $42.70
$715k
2.8% of stake
Jan 13No plan
Keith Woods
Chief Operating Officer · sold 16,746 at $42.70
$715k
2.8% of stake
Jan 13No plan
Akshay Vaishnaw
President of R&D · sold 20,438 at $42.70
$873k
3.3% of stake
Jan 13No plan
David Hallal
Chief Executive Officer · sold 57,450 at $42.70
$2.45M
3.2% of stake
Dec 16, 202510b5-1 plan
Katie Peng
Director · sold 1,006 at avg $44.09
$44k
3.0% of stake
Dec 4, 202510b5-1 plan
Mo Qatanani
CHIEF SCIENTIFIC OFFICER · sold 136,462 at $45.21
$6.17M
56% of stake
Oct 7, 2025
Srinivas Akkaraju
Director · bought 29,599 at avg $39.92
$1.18M
0.4% of stake
Oct 3, 2025 – Oct 6, 2025
Srinivas Akkaraju
Director · bought 500,439 at avg $37.58
$18.8M
9.4% of stake
Sep 22, 202510b5-1 plan
Mo Qatanani
CHIEF SCIENTIFIC OFFICER · sold 3,353 at $30.67
$103k
3.0% of stake
Sep 16, 202510b5-1 plan
Katie Peng
Director · sold 1,006 at avg $32.53
$33k
2.9% of stake
Sep 16, 2025No plan
Mo Qatanani
CHIEF SCIENTIFIC OFFICER · sold 3,178 at $33.52
$107k
2.8% of stake
Aug 18, 2025No plan
Caryn Parlavecchio
CHRO · sold 2,178 at $31.17
$68k
1.4% of stake
Jul 16, 202510b5-1 plan
Jeffrey S. Flier
Director · sold 11,136 at $40.02
$446k
32% of stake
Jul 8, 202510b5-1 plan
Mo Qatanani
CHIEF SCIENTIFIC OFFICER · sold 24,066 at $34.44
$829k
17% of stake
Jun 23, 202510b5-1 plan
Jeffrey S. Flier
Director · sold 31,452 at avg $32.58
$1.02M
47% of stake
Jun 16, 202510b5-1 plan
Katie Peng
Director · sold 3,031 at avg $31.97
$97k
8.0% of stake
Jun 16, 2025No plan
Mo Qatanani
CHIEF SCIENTIFIC OFFICER · sold 3,668 at $32.00
$117k
2.6% of stake
Jun 16, 2025No plan
Caryn Parlavecchio
CHRO · sold 6,186 at $32.00
$198k
3.8% of stake
Jun 16, 2025No plan
Junlin Ho
GENERAL COUNSEL · sold 7,442 at $32.00
$238k
3.2% of stake
May 29, 202510b5-1 plan
Jeffrey S. Flier
Director · sold 6,075 at avg $29.73
$181k
12% of stake

How to read this. Insiders sell for many reasons: taxes, diversifying, a house. Open-market buys are rarer and say more. A 10b5-1 plan is a trading schedule set up months in advance, so those sales were not timed on news. Large holders (funds and 10% owners) are listed under Everything but not counted as insiders. If you own or watch SRRK, we send a push when an executive buys or makes a large sale outside a plan.

Source: SEC Form 4 filings, filed within two business days of each trade and checked for new ones every hour.

Related stocks: Biological Products, (No Diagnostic Substances)

ALECAlector Inc.

XFORX4 Pharmaceuticals Inc.

TARSTarsus Pharmaceuticals Inc.

AMGNAmgen Inc.

CHRSCoherus Biosciences Inc.

BDTXBlack Diamond Therapeutics, Inc.

IMAImageneBio, Inc.

VIRVir Biotechnology Inc.

Spot a number that looks wrong? Check it in SRRK's SEC filings or

Download this analysis as a PDF (Pro)

Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.

2 of 2 free stocks used today

Keep analysing SRRK

Create a free account and get 14 days of Premium: every stock and every tool.

Unlimited stocksQuality, fair value and dividends for 10,000+ stocks
Stock screenerFilter on quality, valuation and dividend safety
Portfolio trackerReal return, dividend calendar and portfolio quality
Editable DCFChange the assumptions and watch fair value move
Compare side by sideUp to 10 stocks in one table
Unlimited alertsPrice, P/E, Quality Score and yield

No card. Moves to Free after, unless you upgrade.

Already have an account?

Or come back tomorrow. Stocks on your watchlist are always free to view.